


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-28. (canceled)

29. (currently amended) A dihydropyridine compound wherein at least one of the hydrogen atoms is replaced with a deuterium atom, characterized in that said dihydropyridine compound is deuterated nifedipine having the formula



wherein:

X = H, R¹ = CH₃ wherein each H atom may be replaced by a D atom, and R² = each are CH₃ groups wherein each H atom of each CH₃ group of R¹ and R² wherein at most 5 out of the total 6 H atoms may be replaced by a D atom, and wherein at least one of R¹ and R² together contains a D atom, with the proviso that no more than 11 of 12 H atoms are D atoms and that when all 6 H atoms of R² are D atoms, at least one H atom in the CH₃ groups of R¹ is a D atom.

30. (previously presented) The dihydropyridine of claim 29 wherein at least one of the methyl groups in the 2,6-position is CD₃.

31. (canceled)

32. (previously presented) A pharmaceutical composition for use as a medicament comprising one or more dihydropyridine compounds of claim 29 as the active ingredient and a pharmaceutically acceptable support.

33. (previously presented) The pharmaceutical composition of claim 32 wherein the dihydropyridine compounds are characterized in that at least one of the methyl groups in the 2,6-position is CD₃.

34. (canceled)

35. (currently amended) A calcium channel blocking deuterated 1,4-dihydropyridine compound selected from nifedipine and nicardipine with an extended duration of action compared with a non-deuterated nifedipine and nicardipine, respectively, wherein ~~one or more~~ at least one but at most 5 of the 6 hydrogen atoms of ~~one or both of~~ the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

36. (canceled)

37. (currently amended) A method of extending the duration of action of a calcium channel blocking undeuterated 1,4-dihydropyridine compound selected from nifedipine and nicardipine whereby ~~one or more~~ at least one but at most 5 of the 6 hydrogen atoms of ~~one or both of~~ the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

38. (canceled)

39. (currently amended) A calcium channel blocking deuterated 1,4-dihydropyridine compound selected from nifedipine and nicardipine with an enhanced use dependency compared with a non-deuterated nifedipine and nicardipine, respectively, whereby ~~one or more~~ at least one but at most 5 of the 6 hydrogen atoms of ~~one or both of~~ the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

40. (canceled)

41. (currently amended) A method of enhancing the use dependency of a calcium channel blocking 1,4-dihydropyridine compound selected from nifedipine and nicardipine, compared with a non-deuterated nifedipine and nicardipine, respectively, ~~whereby one or more~~ by deuterating at least one but at most 5 of the 6 hydrogen atoms of ~~one or both of~~ the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

42. (canceled)

43. (currently amended) A method of modifying the dose-response relationship of a calcium channel blocking 1,4-dihydropyridine compound selected from nifedipine and nicardipine, compared with a non-deuterated nifedipine and nicardipine, respectively, ~~whereby one or more~~ by deuterating at least one but at most 5 of the 6 hydrogen atoms of ~~one or both of~~ the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

44. (canceled)